These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

840 related items for PubMed ID: 17698090

  • 1. Management of low grade papillary bladder tumors.
    Herr HW, Donat SM, Reuter VE.
    J Urol; 2007 Oct; 178(4 Pt 1):1201-5; discussion 1205. PubMed ID: 17698090
    [Abstract] [Full Text] [Related]

  • 2. Does the management of bladder perforation during transurethral resection of superficial bladder tumors predispose to extravesical tumor recurrence?
    Skolarikos A, Chrisofos M, Ferakis N, Papatsoris A, Dellis A, Deliveliotis C.
    J Urol; 2005 Jun; 173(6):1908-11. PubMed ID: 15879773
    [Abstract] [Full Text] [Related]

  • 3. Pathologic features of bladder tumors after nephroureterectomy or segmental ureterectomy for upper urinary tract transitional cell carcinoma.
    Raman JD, Sosa RE, Vaughan ED, Scherr DS.
    Urology; 2007 Feb; 69(2):251-4. PubMed ID: 17320658
    [Abstract] [Full Text] [Related]

  • 4. Conservative management of low risk superficial bladder tumors.
    Pruthi RS, Baldwin N, Bhalani V, Wallen EM.
    J Urol; 2008 Jan; 179(1):87-90; discussion 90. PubMed ID: 17997444
    [Abstract] [Full Text] [Related]

  • 5. A surveillance schedule for G1Ta bladder cancer allowing efficient use of check cystoscopy and safe discharge at 5 years based on a 25-year prospective database.
    Mariappan P, Smith G.
    J Urol; 2005 Apr; 173(4):1108-11. PubMed ID: 15758711
    [Abstract] [Full Text] [Related]

  • 6. Stage Ta-T1 bladder cancer: the relationship between findings at first followup cystoscopy and subsequent recurrence and progression.
    Holmang S, Johansson SL.
    J Urol; 2002 Apr; 167(4):1634-7. PubMed ID: 11912378
    [Abstract] [Full Text] [Related]

  • 7. The relationship among multiple recurrences, progression and prognosis of patients with stages Ta and T1 transitional cell cancer of the bladder followed for at least 20 years.
    Holmäng S, Hedelin H, Anderström C, Johansson SL.
    J Urol; 1995 Jun; 153(6):1823-6; discussion 1826-7. PubMed ID: 7752327
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Watchful waiting policy in recurrent Ta G1 bladder tumors.
    Gofrit ON, Pode D, Lazar A, Katz R, Shapiro A.
    Eur Urol; 2006 Feb; 49(2):303-6; discussion 306-7. PubMed ID: 16413659
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Ta T1 low and intermediate transitional cell carcinoma of the bladder: recurrence rates and the timing of check cystoscopies within the first year.
    Guney S, Guney N, Canogullari Z, Ergenekon E.
    Urol Int; 2008 Feb; 80(2):124-8. PubMed ID: 18362479
    [Abstract] [Full Text] [Related]

  • 20. Tumor progression and survival of patients with high grade, noninvasive papillary (TaG3) bladder tumors: 15-year outcome.
    Herr HW.
    J Urol; 2000 Jan; 163(1):60-1; discussion 61-2. PubMed ID: 10604314
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 42.